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Abstract
Rheumatoid arthritis is a multisystemic auto-inflammatory disease
affecting up to 1% of the population and leading to the destruction
of the joints. Evidence exists for the involvement of the innate as
well as the adaptive immune systems in the pathology of the
disease. The success of anti-tumour necrosis factor-α indicates the
importance of pro-inflammatory mediators produced by innate
immune cells in rheumatoid arthritis progression. Therefore,
considerable efforts have been made in elucidating the signalling
pathways leading to the expression of those mediators. This review
will concentrate on the role of signalling pathways in innate immune
cells in the context of rheumatoid arthritis.
Introduction
The immune system evolved as a mechanism to protect
organisms from infection by pathogenic organisms and other
harmful substances. In general, the immune system is capable
of recognising invading pathogens and their products as well
as endogenous danger signals [1]. This recognition results in
the initiation of an immune response, which will under normal
circumstances eliminate the insult without further damage to
the host. However, it is now well recognised that defects in
regulating inflammation can lead to an excessive response to
infectious agents, such as sepsis, or auto-inflammatory
diseases, such as rheumatoid arthritis (RA).
In the context of RA numerous cellular mechanisms and
signalling pathways drive the chronic inflammation observed
in this disease, and current evidence suggests an involve-
ment of the innate as well as the adaptive immune systems in
RA pathology. The importance of the adaptive immune
response is supported by rodent models of disease, such as
collagen-induced arthritis (CIA), that are mainly Th1- and/or
Th17-driven [2]. Mice lacking IL-23 do not develop CIA [3]
and CCR6-expressing Th17 cells are preferentially recruited
to inflamed joints [4]. In humans, the efficacy of anti-CD20
(Rituximab) and anti-CTLA4 (Abatacept) antibodies in RA
treatment suggest a function for activated B and T cells in RA
[5,6]. Moreover, a role for CD4+ T cells in RA pathogenesis is
inferred by the strong HLA-DR association [7].
During the progression of RA the production of cytokines,
chemokines and matrix metalloproteinases by mainly innate
immune cells leads to the destruction of cartilage and bone.
Currently, the most successful RA therapeutics are the
biologicals Infliximab, Etanercept and Adalimumab [8], which
block tumour necrosis factor (TNF)α, a cytokine produced
mainly by macrophages [9]. The importance of TNFα in
disease pathogenesis has also been shown in murine models
of the disease [10,11]. Given the success of anti-TNFα
therapy, there has been a great deal of interest in elucidating
the pathways driving the production of this cytokine as well
as other inflammatory mediators in RA. Other innate immune
cells that may have a role in RA include neutrophils [12], mast
cells [13] and natural killer cells [14]. They have been shown
to be present in high numbers and widely distributed in
synovial fluid and tissues. These cells are able to produce
several cytokines that may be involved in the pathogenesis of
disease, but their contribution to pathogenesis is poorly
understood.
This review will describe inflammatory signalling mechanisms
in innate immune cells, and concentrate on the emerging
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evidence implicating certain signalling pathways in driving the
continuous production of pro-inflammatory mediators in the
RA joint.
The danger signal hypothesis
The main role of toll-like receptors (TLRs) is considered to be
the recognition and response to microbial pathogens, but
they have also been reported to recognise endogenous
ligands (reviewed in [15-20]). Endogenous ligands are
thought to be released during necrotic cell death induced by
tissue damage, stress factors or infection, resulting in the
release of cell components that initiate an inflammatory
response [21]. The contents released from necrotic cells may
activate TLRs, generating further inflammation and thus more
necrosis. This cycle of inflammation may explain the chronic
inflammatory state found in autoimmune diseases such as
RA. Indeed, endogenous TLR ligands, such as hyaluronan
oligosaccharides, fibronectin fragments, heat shock proteins,
antibody-DNA complexes and high mobility group box
(HMGB)-1, have all been identified in the RA joint [22-25]
and several studies emphasise a role for TLRs in the
promotion of systemic lupus erythematosus, asthma, Crohn’s
disease, multiple sclerosis, type 1 diabetes, and RA [18].
TLR signalling driving inflammation in RA
Given the existing evidence of an involvement of TLRs in the
pathogenesis of RA and other inflammatory diseases, a great
deal of interest exists in understanding the molecular basis of
the signalling pathways induced by these receptors, with the
hope of identifying therapeutic targets.
Due to their structural similarities TLRs share certain signal-
ling pathways with the IL-1R family [26]. TLR and IL-1R
signalling is initiated by ligand-induced hetero- or homo-
dimerisation of the receptors or association with accessory
proteins [27]. The signal is transduced by the intracellular
Toll/IL-1 receptor (TIR) domain, present in TLRs as well as
IL-1Rs, through the recruitment of TIR domain-containing
adaptor molecules [28]. The TLRs use distinct combinations
of these adaptors to turn on the common TLR/IL-1R pathway
as well as pathways unique to TLRs, leading to the activation
of transcription factors (Figure 1).
MyD88 dependent TLR/IL-1R signalling
IL-1Rs and all TLRs, with the exception of TLR3, share a
common signalling pathway that depends on the adaptor
molecule MyD88 (Myeloid differentiation primary response
gene 88) [28-31]. It has originally been identified as a protein
induced during myeloid differentiation [32] but has since
been shown to be recruited to IL-1Rs and most TLRs through
its carboxyl terminal TIR domain [28,30]. In addition, MyD88
contains an amino-terminal death domain that is responsible
for the recruitment of downstream signalling mediators,
including IL-1R associated kinase (IRAK)-1, IRAK4 and TNF
receptor associated factor (TRAF)6 to the receptor complex
[28,30]. Ultimately, this leads to the activation of mitogen-
activated protein kinases (MAPKs) as well as nuclear factor
(NF)-κB and the transcription of inflammatory mediators such
as TNFα [26] and the stabilisation of inflammatory response
protein mRNAs through the AU-rich elements in the 3′
untranslated region [33].
The essential role of MyD88 in IL-1R/TLR signal transduction
has been demonstrated in MyD88-deficient mice. In response
to IL-1R and IL-18R stimulation, MyD88-deficient macro-
phages show a loss in NF-κB and MAPK activation, as well
as TNFα and IL-6 production [29]. This has also been
observed for most TLRs, with the exception of TLR3 and
TLR4 [34-37]; TLR3 does not utilise MyD88 for signal
transduction while TLR4 recruits additional adaptor mole-
cules that are responsible for MyD88 independent signalling.
Subsequently, TIR domain homology searches led to the
discovery of Mal (MyD88 adaptor like protein; also termed
TIRAP [38,39]). Mal-deficient mice show a reduction in
TLR4- and TLR2-induced NF-κB activation [40,41]. To date,
Mal is thought to function as a sorting adaptor for TLR2 and
TLR4, recruiting MyD88 to the receptor complex in the
plasma membrane, through its ability to interact with
phosphatidylinositol-4,5-bisphosphate [42] (Figure 1).
Evidence obtained in murine and human models indicate the
involvement of the MyD88-dependent signalling pathway in
the pathology of RA. TLR2 knockout and MyD88 knockout
mice are protected from streptococcal cell wall-induced joint
inflammation since these animals do not develop joint
swelling [43,44]. Furthermore, intra-articular administration of
peptidoglycan or lipopolysaccharide, the ligands for TLR2
and TLR4, respectively, results in destructive arthritis in mice,
which is also dependent on MyD88 [45,46]. The IL-1R
antagonist (IL-1RA) knockout mice model displays un-
controlled IL-1 signalling and leads to the development of
chronic arthritis [47]. The arthritis observed in those mice is
markedly reduced when backcrossed to TLR4-deficient but
not TLR2-deficient mice, suggesting a TLR4-specific function
in this model [48]. Furthermore, blocking TLR4 signalling with
a naturally occurring antagonist in mice with CIA leads to
reduced disease severity, even when administered after
disease onset [49].
In humans, stimulation of TLR2- and TLR9-expressing RA
synovial fibroblasts with peptidoglycan leads to the
expression of matrix metalloproteinases and secretion of IL-6
and IL-8, while no activation has been observed in response
to the TLR9 ligand CpG oligodeoxynucleotides [50]. Stren-
gthening the role of TLR4 signalling in RA pathogenesis is
the observation that serum and synovial fluid from RA patients
stimulated TLR4 expressing CHO cells to up-regulate CD25
[51]. In accordance with this study are results obtained in RA
synovial membrane cultures, where the over-expression of a
dominant negative construct of MyD88 or Mal inhibits the
spontaneous release of cytokines and matrix metallo-
proteinases [52,53]. Based on these results, increasedPage 3 of 12
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efforts have been made to identify potential endogenous TLR
ligands in the joints of RA patients. Indeed, it has been shown
that conditioned medium from RA synovial membrane
cultures activates human macrophages in a MyD88- and Mal-
dependent manner, further strengthening the involvement of
an endogenous TLR ligand driving RA pathology [52,53]. In
addition to endogenous TLR ligands, exogenous ligands
derived from infections might potentially also play a role in
RA, although no ligand has so far been defined.
TRIF dependent TLR signalling
In addition to the MyD88-dependent TLR signalling pathway,
which is shared with the IL-1Rs, TLRs also induce MyD88
independent signalling cascades. Stimulation of cells with
double-stranded RNA or lipopolysaccharide (TLR3- and
TLR4-ligands, respectively) results in the activation of
interferon regulatory factors (IRFs). This is due to the
presence of additional TLR adaptor molecules, which have
been identified through TIR domain homology searches and
Available online http://arthritis-research.com/content/10/5/216
Figure 1
TLR signalling pathways. For simplicity reasons the signalling pathways induced by toll-like receptor (TLR)4, which utilises all four known adaptor
proteins, is shown. Following stimulation and dimerisation, the IL-1R and TLR signalling pathways, with the exception of TLR3, recruit the adaptor
molecule MyD88 and induce nuclear factor (NF)-κB and mitogen-activated protein kinases (MAPKs) through IL-1R associated kinase (IRAK)-4,
IRAK-1 and TNF receptor associated factor (TRAF)-6. In addition, a MyD88-independent signalling pathway is utilised by TLR3 and TLR4, which
depends on the adaptor molecule TRIF (TIR-domain-containing adapter-inducing interferon-β) and leads to the induction of interferon regulatory
factors (IRFs) and a late activation of NF-κB. Signalling through TLR4 results in phosphoprylation and activation of protein tyrosine kinases (TKs).
The Tec family member Btk interacts with the Toll/IL-1 receptor (TIR) domains of TLRs, MyD88 and Mal (MyD88 adaptor like protein). Once
activated, Btk phoshporylates Mal and activates NF-κB and/or p38 MAPK. Src family kinases (SFKs; for example, Hck) are known to function
upstream of both Pyk2 and Syk kinases, respectively, in TLR signalling. TLRs mediate phosphatidylinositol-3-kinase (PI3K) activation that
suppresses p38 MAPK and NF-κB. Inhibition of these signalling cascades by PI3K is possibly mediated by protein kinase B (PKB), and limits the
production of inflammatory cytokines. IKK = IkappaB kinase; RANTES, Regulated on activation, normal T expressed and secreted; TBK, TANK-
binding kinase; TNF, tumour necrosis factor; TRAM, TRIF-related adaptor molecule.include: TRIF (TIR-domain-containing adapter-inducing IFN-β;
also termed TICAM-1), TRAM (TRIF-related adaptor mole-
cule; also termed TICAM2) and SARM (TIR domain-sterile
alpha and HEAT/Armadillo motif) [54].
Stimulation of TLR3 or TLR4 results in the recruitment of
TRIF, and in the case of TLR4 also TRAM [55-57]. The disso-
ciation of TRIF activates a complex consisting of the kinases
IkappaB kinase (IKK)i and TANK-binding kinase (TBK)-1 as
well as the scaffolding protein TRAF3 [58], which ultimately
leads to the activation of IRF-3 and IRF-7 and the expression
of IFN-inducible genes such as those encoding IFN-β, IP10
(inducible protein 10) and RANTES (Regulated on activation,
normal T expressed and secreted) [26,59,60]. Moreover,
TRIF recruitment has also been shown to be responsible for
MyD88-independent activation of NF-κB. However, the exact
mechanism of NF-κB activation by TRIF is still unclear. Some
find that binding of receptor interacting protein (RIP)-1 to the
RIHM (RIP interacting homology motif) domain of TRIF leads
to the induction of NF-κB, while others suggest that an
autocrine effect of TNFα, initially induced through IRF-3, is
responsible for NF-κB activation [61,62].
TRAM is structurally related to Mal and has therefore been
suggested to function as a sorting adaptor, recruiting TRIF to
TLR4 [42,56]. In this context, TRAM has been shown to be
recruited to the plasma membrane by myristoylation [63].
However, a recent study provides evidence that TRAM recruit-
ment is subsequent to the endocytosis of the TLR4 complex
[64]. Therefore, TRAM provides a mechanism that allows
sequential activation of MyD88-dependent signalling while
TLR4 is located in the plasma membrane, followed by TRIF-
dependent signalling after TLR4 internalisation [64] (Figure 1).
SARM is the least investigated TLR adaptor molecule. So far,
no activation function could be assigned to it. However,
recent data describe SARM as an inhibitor of TRIF-
dependent signalling [65]. SARM has been shown to interact
with TRIF and expression of SARM in HEK293 cells led to
the inhibition of TRIF-dependent, but not MyD88-dependent,
NF-κB activation [65].
Some evidence indicates the involvement of the TRIF-
dependent signalling pathway in the pathology of RA due to
TLR3 stimulation. RNA released from necrotic synovial fluid
cells has been shown to activate RA synovial fibroblasts via
TLR3 [66]. Interestingly, RA synovial fibroblasts have been
shown to respond to the TLR3 stimulation by producing
TNFα while primary human skin fibroblasts do not [67]. This
shows that TLR3 is functional in the inflamed synovium and
that TLR3 stimulation could potentially result in the produc-
tion of TNFα in the RA joint.
Other signalling pathways induced by TLRs
Up until now the focus of TLR signalling research has been
on delineating the membrane-proximal adaptor molecules
utilised. But determining the downstream pathways engaged
is important in understanding TLR specificity, as well as
providing therapeutic targets.
The involvement of protein tyrosine kinases (TKs) in TLR
signalling was appreciated even before the TLRs themselves
were discovered [68], but with dozens of TKs found in
mammalian cells the identities of the molecules involved in
TLR signalling have only been revealed recently [69]. There is
good evidence to suggest that Hck [70,71], Btk [72-75],
Bmx [76,77], Syk [78,79] and Pyk2 [80-82] are involved in
TLR signalling, even though the evidence can be hard to
come by due to extensive redundancies found in TKs
(Figure 1). The mechanisms by which these kinases operate
in TLR signalling pathways still need to be resolved.
Concomitantly, a number of TKs have been implicated in the
negative regulation of TLR signalling. For example, members
of the TAM receptor family inhibit both MyD88 and TRIF
pathways by induction of suppressor of cytokine signalling
(SOCS)-1 and -3 [83-85]. In light of these links between TKs
and TLR signalling, the recently discovered TK inhibitors such
as Dasatinib may potentially be useful in blocking harmful
effects of TLR signalling in chronic inflammation [86].
Phosphatidylinositol-3-kinases (PI3Ks) belong to a large
family of lipid signalling kinases that phosphorylate phospho-
inositides and control numerous cellular functions, such as
proliferation, survival and migration [87]. They consist of a
catalytic 110 kDa subunit and a tightly associated 85 kDa
regulatory subunit. PI3Ks become activated in response to
numerous TLR stimuli, including lipopolysaccharide, peptido-
glycan and CpG-DNA, and subsequently induce the phos-
phorylation of Akt/protein kinas B [88,89]. Current data
suggest that the activation of PI3Ks, following TLR stimula-
tion, leads to the inhibition of MAPKs and NF-κB as observed
using chemical inhibitors or over-expression systems [88]
(Figure 1). In the context of RA it is interesting to note that
p110γ-knockout mice are resistant to models of RA and that
the administration of PI3Kγ inhibitors restrain the progression
of inflammation and joint damage [87]. However, the reduced
incidence and severity of RA observed in PI3K-knockout mice
is most likely due to its role in the T- and B-cell compartment
rather than in innate immune cells [87].
It is likely that several TLRs are stimulated in the RA joint due
to the release of numerous ‘danger signals’ following cell
necrosis. The induction of TLR signalling pathways would
subsequently lead to the expression of pro-inflammatory
mediators, including cytokines and chemokines. These
mediators, discussed in the next section, are able to feedback
upon the macrophage to form an autocrine inflammatory loop,
potentiating disease.
Activation of macrophages by cytokines
Several cytokines have a direct effect on monocytes/
macrophages in the context of RA (Table 1) and exert
Arthritis Research & Therapy    Vol 10 No 5 Drexler et al.
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example is IL-15, which exhibits pro-inflammatory activity both
in vitro and in CIA, and when blocked will reduce the inci-
dence of disease [90]. However, this review focuses on six of
those cytokines for which involvement in RA is well charac-
terised: TNFα, IL-1, IL-10, macrophage migration inhibitory
factor (MIF), IL-17, and receptor activator for NF-κB (RANK).
Interleukin-1
The IL-1 family of cytokines plays a significant role in RA and
includes IL-1α, IL-1β, IL-1RA, IL-18, IL-33, and IL-1F5, 6, 7, 8,
9 and 10. IL-1β is a potent pro-inflammatory cytokine with
roles in bone erosion and cartilage degradation, rather than in
synovitis. In a streptococcal cell wall-induced arthritis model,
IL-1-/- mice showed reduced late cellular infiltration and
cartilage damage while joint swelling is unaffected [91]. Also,
by crossing IL-1-/- mice with the TNFα-transgenic model of
arthritis, Zwerina and colleagues [92] showed that IL-1 is
essential for TNFα-mediated cartilage damage and has a
partial role in TNFα-mediated bone damage. IL-1β is able to
activate macrophages to induce the production of cytokines,
reactive oxygen intermediates and prostaglandin (Table 1).
Signalling is mediated through the dimerisation of two
receptors, IL-1RI and IL-1R-AcP. A third receptor, IL-1RII, can
also bind IL-1β but cannot mediate signalling due to a small
cytoplasmic tail and acts as a decoy [93]. IL-1RA can also
bind these receptors and acts as a competitive inhibitor. In
the case of RA, IL-1β is more plentiful than IL-1RA, inducing a
pro-inflammatory state [94]. The intracellular signalling
cascade of IL-1 is similar to that of the MyD88-dependant
TLR cascade discussed previously and involves the induction
of IRAK1, IRAK4, MyD88 and transforming growth factor-
activated kinase (TAK)1 [26]. NF-κB mediates multiple gene
transcription events, and in the context of IL-1β is able to
activate another transcription factor, ESE-1, which modulates
several pro-inflammatory genes [95].
Tumour necrosis factor alpha
TNFα is considered to be the principal inflammatory cytokine
in RA and is the major factor involved in inducing and main-
taining synovitis. It is commonly found at high levels in RA
patients and, as such, has been targeted successfully to
alleviate disease symptoms. TNFα is a cytokine that both
activates and can be produced by macrophages and
therefore forms an autocrine inflammatory effect. As well as
its well-documented effects (Figure 1), TNFα has been
shown to affect both major histocompatibility complex and
Fcγ receptor (FcγR) expression. TNFα is able to reduce the
expression of HLA-DR on myeloid RA cells where this is
brought back to normal upon the addition of anti-TNFα. TNF
treatment of healthy monocytes also reduced HLA-DR and a
mixed lymphocyte reaction [96]. TNFα is able to reduce the
expression of all activating FcγRs in vitro where anti-TNFα
can increase FcγRIIa and IIIa. However, in RA patients, anti-
TNFα therapy is accompanied by an initial reduction in FcγRI
but increases back to normal after therapy is finished [97].
Intra-cellular signalling is mediated through TNF-R1 and TNF-
R2, which upon binding of TNFα will recruit several signalling
molecules [98]. TRAF2 is recruited to the receptor and in
conjunction with TAK1 is able to activate a signalling cascade
resulting in JNK and c-Jun activation. RIP is recruited to this
receptor complex, which in turn can activate the IKK signalo-
some to activate NF-κB. IKK2 and the p50 subunit of NF-κB
Available online http://arthritis-research.com/content/10/5/216
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Table 1
Effects of cytokines on macrophages/monocytes during rheumatoid arthritis
Monocyte/macrophage iNOS/NO 
Cytokine activation Cytokine release ROI release PG release release MHC expression FcγRs
IL-1 ↑↑ ↑ ↑
IL-7 ↑
IL-10 ↑/↓↑ ↓ ↑ ↑
IL-15 ↑ or ↓ (dose dependant)
IL-17 ↑↑ ↑ ↑
IL-18 ↑↑
IL-32 ↑↑
MIF ↑↑ ↑
TGFβ Early ↑, then ↓
TNFα↑ ↑ ↑ ↓ ↓
Type-I IFNs ↑ ↑
Up and down arrows indicate increase and decrease, respectively. FcγRs, Fcγ receptors; iNOS, inducible nitric oxide synthase; MHC, major
histocompatibility complex; MIF, macrophage migration-inhibitory factor; NO, nitric oxide; PG, prostaglandin; ROI, reactive oxygen intermediates;
TGF, transforming growth factor; TNF, tumour necrosis factor. Adapted from [159].have been shown to be essential for this process, while IKK1
is not [99,100]. TRADD (TNFR-associated via death domain)
and FADD (Fas-associated protein with death domain) are
also recruited to the receptor signalling complex to induce
apoptosis. NF-κB inducing kinase is another TNF receptor-
associated factor described in TNFα induction, but has
proven to be non-essential [101]. Zwerina and colleagues
[102] recently showed that p38 MAPK was essential for
TNFα-mediated bone degradation through affecting osteo-
clast differentiation, but did not specify if this involves the
activation of macrophages.
Macrophage migration inhibitory factor
MIF is able to activate and recruit macrophages during RA. It
is the essential factor in RA fibroblast-conditioned medium for
TNFα induction in monocytes [103]. This is mediated through
CD74, the subsequent engagement of p38 MAPK, ERK, Src
kinase, phospholipase A2 and PI3K pathways [104-108], and
the binding of NF-κB and AP-1 to DNA to effect gene
transcription [109]. MIF has been shown to be an endoge-
nous antagonist of glucocorticoids (reviewed in [110,111]);
by inhibiting the latter, MIF enhances the inflammatory state
through p38 MAPK and MAPK phosphatase 1 (MKP1) [112],
which in turn deactivates p38, JNK and ERK. MKP1-
deficiency has been associated with exacerbation of CIA
[113], potentially by affecting MIF signalling. MIF is also able
to negatively regulate p53 [114] through cyclooxygenase 2
[115] and the PI3K/Akt pathway [116] to arrest cell-
apoptosis. Finally, MIF recruits monocytes/macrophages to
the site of inflammation through CCL2 induction [117], or
acting as a chemokine ligand on endothelial cell surfaces by
directly binding to CXCR2 [118].
IL-10: anti- or pro-inflammatory in rheumatoid arthritis?
IL-10 is widely considered to be a powerful anti-inflammatory
cytokine that is able to suppress the production of TNFα, IL-6
and IL-1 from macrophages. Its role in RA disease-associated
macrophages, however, is controversial. Human IL-10 has
little effect when used to alleviate disease in RA patients. On
the contrary, circulating monocytes have been shown to
upregulate the expression of FcγRI and FcγRIIa in response
of IL-10 [119,120], which may potentially enhance disease.
IL-10 has also been shown to upregulate various genes
associated with pro-inflammatory function, as well as the IFN-
γ-inducible genes [121]. In response to IL-10, RA macro-
phages upregulate TNF receptor (TNFR)1 and TNFR2 mRNA
and produce elevated levels of IL-1β and IL-6 in response to
TNFα and macrophage-colony stimulating factor [122].
However, others suggest that IL-10 upregulates the soluble
form of the TNFR rather than the membrane bound form,
which in turn would inhibit inflammation [123]. To confound
the matter further, it has been shown repeatedly that in whole
RA synovial cultures the addition of IL-10 suppresses the
level of TNFα and IL-1β two- to three-fold [124] (reviewed in
[125]), in sharp contrast to the RA macrophage phenotype.
IL-10 treatment of CIA mice has also been shown to inhibit
disease progression [126]. Overall, this suggests that
arthritic macrophages may have altered signalling patterns
when compared to other cell types, and IL-10 may have both
anti- and pro-inflammatory functions in RA.
In macrophages the principal intracellular mediator of sup-
pressive effects of IL-10 is STAT3 [127]. IL-10 binds to the
IL-10R1/IL-10R2 receptor complex and recruits both Jak1
and Tyk2 to activate STAT3 [125]. The tyrosine residues
contained within the YXXQ-STAT3-docking site on IL-10R1
were found to be essential for this interaction [128]. The
mechanism of IL-10 suppressive activity is unclear [125].
IL-10 has been reported to reduce the activity of the IKK
signalosome and induce the translocation of NF-κB p50:p50
homodimers, resulting in a suppression of NF-κB-mediated
gene transcription [129]. However, our own studies have
found no effect on the activation of NF-κB [125,130]. It
should also be noted that IL-10 is able to strongly induce the
expression of SOCS-3, a classic suppressor of cytokine
signalling [121]. However, the role for SOCS-3 in mediating
the effect of IL-10 is undetermined as the cytokine is still
functional in SOCS-3-/- mice [131].
Interleukin-17
CD4+ helper T cells that secrete IL-17 are at the centre of an
orchestra of cellular interactions that mediate acute inflamma-
tion in many autoimmune diseases. This has renewed the
interest in understanding signalling by the IL-17 receptor,
which is found in macrophages [132] and synovial fibroblasts
[133]. As with other cytokines, the IL-17 receptor is a
complex of at least two separate proteins, IL-17RA and
IL-17RC [134]. These, together with IL-17RB, RD and RE,
form a distinct receptor superfamily with little similarity to
other cytokine receptors. Likewise, there are no fewer than six
members in the IL-17 cytokine family (reviewed in [135]). Two
of them, IL-17A and IL-17F, are secreted by Th17 cells. A
third one, IL-17E or IL-25, is associated with Th2 responses.
The functions of the other family members are unknown at the
moment.
It has been suggested that the IL-17 receptor chains are pre-
assembled before ligand binding [136], but the details are
murky. So are the intracellular signalling pathways utilized by
IL-17R. IL-17RA has a long cytoplasmic tail, but factors that
engage this tail are unknown, with the exception of TRAF6,
which is needed for IL-17 signalling [137]. But as IL-17RA has
little similarity to the TNF receptor superfamily, the structural
basis of this interaction is unclear at this stage. Activation of
NF-κB and MAPK pathways lead to transcription and mRNA
stabilisation of pro-inflammatory molecules; transcription
factors such as AP-1 and c/EPB are also important in
mediating the full activities of IL-17 (reviewed in [138]).
RANK/RANKL/osteoprotegerin
Bone destruction in arthritic conditions can be directly attributed
to osteoclasts, a specialised lineage of macrophages involved in
Arthritis Research & Therapy    Vol 10 No 5 Drexler et al.
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found to be overactive, and this can largely be attributed to the
pro-inflammatory milieu found in RA joints, which includes
excessive RANK ligand (RANKL)-RANK signalling.
RANKL is a member of the TNF superfamily and, corres-
pondingly, RANK belongs to the TNFR superfamily. The
discovery that RANKL-RANK signalling is the key molecular
event in osteoclast differentiation by several independent
groups in the late 1990s [139-142] gave birth to the field of
osteoimmunology. RANKL is normally expressed in
osteoblasts and stromal cells, but in pro-inflammatory environ-
ments, as in RA, RANKL expression is elevated and spreads,
particularly to activated T cells [139,143,144]. This increases
the maturation and activity of osteoclasts, thus tipping the
bone metabolic balance in favour of destruction. A further level
of regulation is provided by osteoprotegerin, which acts as a
soluble decoy receptor of RANKL, and thus is an effective
inhibitor of RANK signalling and osteoclast differentiation
[145,146]. Given the importance of bone destruction as a
cause of morbidity in RA, the RANK-RANKL-osteoprotegerin
triad is now a target for therapeutic intervention.
Characterisation of the signalling pathways utilised by
RANKL-RANK is aided by their similarities to other TNF
superfamily members. In essence, RANK and RANKL are
trimeric molecules; upon ligand binding multiple TRAFs are
recruited, with TRAF6 being the critical adaptor as its absence
incapacitates osteoclasts [147,148]. TRAF6, together with
Gab2 [149], triggers NF-kB, Akt and Jnk pathways.
Ultimately, expression of osteoclastogenic genes is switched
on by a cascade of transcription factors that include NF-κB,
NFATc1, c-Fos [150,151] and osterix [152].
T cell-mediated activation of the innate
immune cells
The role of T cells in RA pathogenesis has been questioned
by some, but as cited earlier it is now accepted that
autoreactive T cell activation is essential in the development
of the full blown disease both in human and animal models.
However, it is unclear what the relative contributions from
T cell-derived versus TLR- or cytokine-derived signals are.
Perhaps T cells prime the initial inflammation; once tissue
damage is occurring other signals take over in the main-
tenance and amplification of inflammation at disease sites.
The signals innate immune cells receive from arthritogenic
T cells are still being worked out. Some of the soluble factors,
such as IL-17 and RANK, have already been covered, but
they clearly are not the whole story. For example, RA T cells
have been shown to induce TNFα production in monocytes in
a direct cell-contact, PI3K-dependent manner [153-155].
Separately, but perhaps in a related finding, it was found that
T cells generate microparticles that can promote cytokine
production in macrophages [156]. The molecular basis of
these phenomena is still being worked out; molecules such
as CD40L and membrane bound-TNFα have been implicated
[157,158]. Modelling this interaction in vitro is difficult as the
outcome is highly dependent on the status of both T cells and
macrophages [155,158]. It is likely that in vivo studies will be
needed to resolve this question.
Conclusion
RA is an auto-inflammatory disease where multiple mecha-
nisms of the immune system play a role in its pathology.
Current evidence in human suggests a strong influence of
innate immune cells, such as macrophages and synovial
fibroblasts, in the progression of disease, as they produce
large amounts of pro-inflammatory mediators leading to the
destruction of the cartilage and bone.
Given the success of anti-TNFα therapy, there has been a
great deal of interest in elucidating the pathways driving the
production of this cytokine as well as other inflammatory
mediators in RA. However, the continuous and systemic
blockade of a cytokine results in unwanted side effects, such
as increased infections. Current research on a new
generation of anti-inflammatory drugs has focused on
blocking intracellular signalling pathways, for example,
NF-κB/IKK2 and p38 MAPK. However, no compounds have
succeeded in the clinic so far. A major problem could be that
both these kinases are ubiquitously expressed, which may
lead to side effects. Therefore, there is a need for more
specific targets that would either affect specific parts of the
immune response, act only in specific tissues/cells or would
actually lead to the complete resolution of the chronic
inflammation. The use of specific blocking antibodies as well
as emerging technologies such as small interfering RNA will
expand our knowledge on particular signalling transducers in
the context of the disease. Therefore, further elucidation of
the signalling pathways driving chronic inflammation in
disease-relevant models could potentially lead to the
identification of therapeutic targets.
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